Jpmorgan Chase & CO Enlivex Therapeutics Ltd. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Enlivex Therapeutics Ltd. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 231 shares of ENLV stock, worth $293. This represents 0.0% of its overall portfolio holdings.
Number of Shares
231
Previous 7,151
96.77%
Holding current value
$293
Previous $27,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ENLV
# of Institutions
22Shares Held
2.1MCall Options Held
16.1KPut Options Held
3.4K-
Armistice Capital, LLC New York, NY1.7MShares$2.16 Million0.03% of portfolio
-
Morgan Stanley New York, NY245KShares$311,0120.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny71.7KShares$91,0450.0% of portfolio
-
Xtx Topco LTD London, X024.8KShares$31,5210.0% of portfolio
-
Act Capital Management, LLC Wayne, PA15KShares$19,0500.09% of portfolio
About Enlivex Therapeutics Ltd.
- Ticker ENLV
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,403,200
- Market Cap $23.4M
- Description
- Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...